Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year guidance.

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

Sales grew 38% year over year, driven by volume growth from weight-loss and diabetes drugs Zepbound and Mounjaro, Lilly said.

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Redditors are complaining their long-term Mounjaro use is causing their hair to fall out in clumps. Experts claim sorting your diet out may fix the issue.

你是不是也经常听到身边的朋友或家人抱怨，糖尿病不仅让他们每天都要小心翼翼地控制饮食，还要时刻担心心脏病的风险？这可不是杞人忧天。心血管疾病仍然是2型糖尿病患者的主要死因。但好消息来了，Eli Lilly公司的一款新药Mounjaro在最近的一项临床试验中大放异彩，可能会成为他们的新希望。 GLP-1受体激动剂，比如诺和诺德的Ozempic，已经证明能有效降低2型糖尿病患者的血糖水平，并且还能减少心 ...

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro was about as good at preventing heart attacks and strokes as its older ...

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...